Stocktoria
NEONC TECHNOLOGIES HOLDINGS, INC. NTHI
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $39,990 at a -155404.4% net margin.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| LYEL | Lyell Immunopharma, Inc. | 1/9 | -13.93 | — | — |
| IBO | IMPACT BIOMEDICAL INC. | 3/9 | -2.38 | — | — |
| TLPH | TALPHERA, INC. | 4/9 | — | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
About NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
FAQ
Is NTHI financially healthy?
NEONC TECHNOLOGIES HOLDINGS, INC.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does NTHI pay a dividend?
No, NEONC TECHNOLOGIES HOLDINGS, INC. does not currently pay a dividend.
How profitable is NTHI?
In FY2025, NEONC TECHNOLOGIES HOLDINGS, INC. had a net margin of -155404.4%.
What is the analyst price target for NTHI?
The average Wall-Street price target for NEONC TECHNOLOGIES HOLDINGS, INC. is $16.00, about 362.4% above the recent price, from 3 analysts.
Is NTHI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEONC TECHNOLOGIES HOLDINGS, INC.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.